JDRF, Novocell form partnership to clinical test encapsulated human islets.
JDRF says the encapsulation procedure potentially provides an approach to avoid the use of chronic immunosuppressive drugs in the islet cell setting. While adults are able to tolerate the side effects produced by the drugs, children are less able to tolerate them making inappropriate candidates for islet cell transplantation.
Novocell encapsulation technology uniformly coats donated pancreatic islets with a thin layer of biocompatible material. The company believes the coats enables implanted cells to survive subcutaneously and controls glucose levels in patients with type 1 diabetes, resulting in near normal hemoglobin A1c levels without the need for life-long immunosuppression.
Contact: Web site: www.novocell.com; www.jdf.org
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Juvenile Diabetes Research Foundation|
|Article Type:||Brief article|
|Date:||Jun 16, 2006|
|Previous Article:||Pharming receives orphan drug designations from FDA for rhC1INH use in treating DGF after organ transplantation.|
|Next Article:||Stem Cell Innovations opens facility in Leiden, The Netherlands.|